Genelux Co. (NASDAQ:GNLX – Get Free Report) Director John Thomas sold 3,334 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $24.99, for a total transaction of $83,316.66. Following the transaction, the director now directly owns 475,793 shares in the company, valued at approximately $11,890,067.07. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
John Thomas also recently made the following trade(s):
- On Friday, September 15th, John Thomas sold 3,333 shares of Genelux stock. The shares were sold at an average price of $21.90, for a total transaction of $72,992.70.
Genelux Stock Up 12.3 %
Genelux stock traded up $2.77 during trading hours on Monday, hitting $25.38. 665,938 shares of the company traded hands, compared to its average volume of 115,093. Genelux Co. has a 1-year low of $5.35 and a 1-year high of $40.98. The firm’s 50-day simple moving average is $24.55 and its two-hundred day simple moving average is $26.73.
Analyst Upgrades and Downgrades
Separately, Maxim Group began coverage on shares of Genelux in a research note on Tuesday, September 12th. They set a “buy” rating and a $40.00 target price on the stock.
Hedge Funds Weigh In On Genelux
Large investors have recently made changes to their positions in the business. BlackRock Inc. boosted its stake in Genelux by 884.8% in the 2nd quarter. BlackRock Inc. now owns 142,799 shares of the company’s stock worth $4,672,000 after purchasing an additional 128,298 shares during the period. Hohimer Wealth Management LLC acquired a new position in shares of Genelux in the 1st quarter valued at about $1,247,000. State Street Corp increased its holdings in shares of Genelux by 493.1% in the 2nd quarter. State Street Corp now owns 45,665 shares of the company’s stock valued at $1,494,000 after purchasing an additional 37,965 shares during the period. Geode Capital Management LLC acquired a new position in shares of Genelux in the 1st quarter valued at about $1,046,000. Finally, Barclays PLC acquired a new position in shares of Genelux in the 1st quarter valued at about $920,000. Institutional investors own 10.77% of the company’s stock.
Genelux Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.
- Five stocks we like better than Genelux
- CD Calculator: Certificate of Deposit Calculator
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What is a Secondary Public Offering? What Investors Need to Know
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How to Calculate Inflation Rate
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.